Drugs /

vinblastine

Back to Drugs List

Overview

Generic Name(s):
vinblastine
Trade Name(s):
Velban and Velsar
NCI Definition [1]:
A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)

Clinical Trials

View Clinical Trials for vinblastine

Vinblastine has been investigated in 16 clinical trials, of which 14 are open and 2 are closed. Of the trials investigating vinblastine, 2 are phase 1/phase 2 (2 open), 10 are phase 2 (9 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (2 open).

TNFRSF8 Expression, PML-RARA Fusion, and t(15;17)(q22;q12) are the most frequent biomarker inclusion criteria for vinblastine clinical trials.

Classical hodgkin lymphoma, bladder carcinoma, and bladder urothelial carcinoma are the most common diseases being investigated in vinblastine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Vinblastine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Vinblastine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vinblastine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Velban, Velsar, vinblastine (product), vinblastinum, (2alpha,2'beta,3beta,4alpha,5beta)-vincaleukoblastine, vinblastine [chemical/ingredient], vincaleukoblastine, vinblastina, vinblastine, vlb, vinblastine, vbl, 865-21-4, vincaleucoblastine, vinblastine, vinblastine (substance), vinblastin, vincaleukoblastine
Drug Categories [2]:
Antimicrotubule agents
NCIT ID [1]:
C930
SNOMED ID [1]:
F-61C11

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.